Phase 2 N=9 Unacylated Ghrelin to Improve FuncTioning in PAD: The GIFT Trial
Peripheral Artery Disease · PAD · Peripheral Arterial Disease
Primary: Levels of Unacylated Ghrelin — 71.34; 58.01; 59.96; 845.57 pg/ml
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=50 A Sequential Two-Stage Dose Escalation Study to Evaluate the Safety and Efficacy of Ruxolitinib
Myelomonocytic Leukemia
Primary: The Maximum Tolerated Dose (MTD) of Ruxolitinib for the Treatment of Myelomonocytic Leukemia (CMML) — 40 mg
Phase 2 N=19 Cetuximab in Treating Patients With Precancerous Lesions of the Upper Aerodigestive Tract
Head and Neck Cancer · Precancerous Condition
Primary: Number of Participants With Objective Response Based on Histologic Grade — 13; 6 Participants
Phase 2 N=90 The Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men With Biochemically Relapsed Hormone Sensitive Prostate Cancer
Prostate Cancer
Primary: Change From Baseline in Functional Assessment of Cancer Therapy - Prostate (FACT-P) Total Score at 12 Months — -8.04; -6.60; -9.42 Units on a scale
Phase 2 N=78 Pasireotide in Prevention of GI Toxicity
Hematological Malignancies
Primary: Percentage of GI Toxicity From the Preparatory Regimen and the GVHD Prophylaxis in Stem Cell Transplantation (SCT) Patients Who Are Treated With Pasireotide — 21…
Phase 2 N=3 Targeting Pulsatile Load to Increase Exercise Capacity and Quality of Life After Aortic Valve Replacement for Severe Aortic Stenosis (PULSE AS)
Aortic Valve Stenosis
Primary: Total Work Performed During a Maximal-effort Exercise Test
Phase 2 N=16 Study of Combination of Ipilimumab and Nivolumab in Patients With Melanoma
Melanoma
Primary: Relapse-Free Survival — 12 Participants
Phase 2 N=9 Study of Efficacy and Safety of Osilodrostat in Cushing's Syndrome
Cushing's Syndrome · Ectopic Corticotropin Syndrome · Adrenal Adenoma
Primary: Percent Change in the Mean Urine Free Cortisol (mUFC) at the Individual Level at Week 12 — -99.0; -97.8; -94.5; -91.5 percentage change
Phase 2 N=305 Phase 2a, Dose-ranging Study With PF-05221304 in Nonalcoholic Fatty Liver Disease (NAFLD)
Nonalcoholic Fatty Liver Disease · Nonalcoholic Steatohepatitis
Primary: Percent Change From Baseline in Liver Fat by Magnetic Resonance Imaging-Proton Density Fat Fraction (MRI- PDFF) at Week 16 — -7.2; -17.1; -49.9; -55.9 Percent change
Phase 2 N=258 A Multi-center 12-week Study of HMS5552 in T2DM
Diabetes Mellitus, Type 2
Primary: After 12-week Treatment, the Change From Baseline in HbA1c — -0.39; -0.65; -0.79; -1.12 Percentage of glycated hemoglobin
Phase 2 N=13 Cabozantinib-S-Malate in Treating Patients With Recurrent or Progressive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Fallopian Tube Clear Cell Adenocarcinoma · Ovarian Clear Cell Adenocarcinoma · Recurrent Fallopian Tube Carcinoma
Primary: The Percentage of Patients Who Survive Progression Free for at Least 6 Months — 23 percentage of participants
Phase 2 N=34 Chlortalidone and Bumetanide in Advanced Chronic Kidney Disease: HEBE-CKD Trial
Renal Insufficiency, Chronic
Primary: Change in Total Body Water — -0.075; -4.36 litres — p=<0.001
Phase 2 N=618 Safety and Immunogenicity Study of Trivalent P2-VP8 Subunit Rotavirus Vaccine in Adults, Toddlers and Infants
Healthy
Primary: Number of Participants Experiencing Adverse Events (AE) Within 28 Days of Any Vaccination — 0; 0; 0; 0 Participants
Phase 2 N=13 Study of PNT2258 for Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma
Lymphoma, Non-Hodgkin's
Primary: Overall Response Rate — 53.8 percentage of participants
Phase 2 N=64 Ipilimumab + Temozolomide in Metastatic Melanoma
Metastatic Melanoma
Primary: 6-Month Progression-Free Survival (PFS) Rate — 29 participants